Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGT | O15294 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1694849 | 0.72 | OGT (0.48) | OGTCA12CA1CA2CA9 | |
| SCHEMBL1694856 | 0.72 | KDM4E (0.55) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL21044565 | 0.72 | OGT (0.53) | OGTCA12CA1CA2CA9 | |
| SCHEMBL28397648 | 0.71 | POLB (0.51) | CA1CA2CA9MAPTSLC6A3 | |
| SCHEMBL28289664 | 0.70 | FABP4 (0.55) | CA1CA2CA9MAPTSLC6A3 | |
| SCHEMBL16719847 | 0.69 | KMT2A (0.47) | CA1CA2CA9MAPTSLC6A3 | |
| SCHEMBL1808749 | 0.69 | ALDH1A1 (0.42) | CA12CA1CA2CA9MAPT | |
| SCHEMBL28116020 | 0.69 | BCHE (0.66) | OGTCA12CA1CA2CA9 | |
| SCHEMBL1457814 | 0.68 | ALDH1A1 (0.58) | MAPTHDAC1KMT2AALDH1A1ALDH1A3 | |
| SCHEMBL16719335 | 0.68 | MYC (0.58) | CA1CA2CA9MAPTSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258314-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2025-03-25 | — | — | US | disclosed |
| US-20220396551-A1 | EBNA1 Inhibitors and Their Method of Use | WISTAR INST (US) | 2022-12-15 | — | — | US | disclosed |
| US-11242317-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2022-02-08 | — | — | US | disclosed |
| EP-3068758-B1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | WISTAR INST (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20200181078-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | WISTAR INST (US) | 2020-06-11 | — | — | US | disclosed |
| US-10421718-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180086699-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-9856214-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160289185-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-06 | — | — | US | disclosed |
| EP-3068758-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | The Wistar Institute Of Anatomy And Biology (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015073864-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258314-B2 | EBNA1 inhibitors and their method of use | EBNA1BP2, MLLT1, PML | OGT 4539/4885CA12 3220/4885CA1 3628/4885 |
| US-11242317-B2 | EBNA1 inhibitors and their method of use | EBNA1BP2, MLLT1, PML | OGT 4539/4885CA12 3220/4885CA1 3628/4885 |
| US-20160289185-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | MCM5, EBNA1BP2, MLLT1 | OGT 4510/4885CA12 3416/4885CA1 3665/4885 |
| US-20200181078-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | EBNA1BP2, MLLT1, PML | OGT 4539/4885CA12 3220/4885CA1 3628/4885 |
| US-10421718-B2 | EBNA1 inhibitors and their method of use | EBNA1BP2, MLLT1, PML | OGT 4539/4885CA12 3220/4885CA1 3628/4885 |
| US-20180086699-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | EBNA1BP2, MLLT1, PML | OGT 4539/4885CA12 3220/4885CA1 3628/4885 |
| US-20220396551-A1 | EBNA1 Inhibitors and Their Method of Use | EBNA1BP2, MLLT1, PML | OGT 4539/4885CA12 3220/4885CA1 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.